RARE (Ultragenyx Pharmaceutical Inc.) שיעור רווח גולמי

This chart of gross profit as a percentage of revenue reflects the strategic acquisitions and commercialization of orphan drugs by Ultragenyx Pharmaceutical (RARE) management. The foundation relies on patent protection and lobbying, despite stringent FDA oversight. However, a narrow patient market and R&D expenses create financial pressure. Today, 78.20 expresses the current value of the metric, helping to define the long-term investment horizon.
פילוחי מדדים פיננסיים ומדדי שוק עבור Ultragenyx Corp (RARE)

To identify the sector's fundamental leaders, the analyst evaluates the business's ability to generate excess cash flow after covering direct production costs. This metric measures the share of sales profit which, in the case of Ultragenyx Pharmaceutical (RARE), is supported by the stability of humanitarian developments independent of geopolitical risks, as clearly evidenced by the gross profit margin.